Disease:
Cardiomyopathy, Hypertrophic

Overview

Alternate Names: 
Synonym
Asymmetric Septal Hypertrophies; Asymmetric Septal Hypertrophy; Cardiomyopathies, Hypertrophic; Cardiomyopathies, Hypertrophic Obstructive; Cardiomyopathy, Hypertrophic Obstructive; HCM - Hypertrophic cardiomyopathy; HOCM - Hypertrophic obstructive cardiomyopathy; Hypertrophic Cardiomyopathies; Hypertrophic Cardiomyopathy; Hypertrophic Obstructive Cardiomyopathies; Hypertrophic Obstructive Cardiomyopathy; Hypertrophic cardiomyopathy; Hypertrophic obstructive cardiomyopathy; Hypertrophies, Asymmetric Septal; Hypertrophy, Asymmetric Septal; IHSS; IHSSs; Idiopathic Hypertrophic Subaortic Stenosis; Idiopathic Hypertrophic Subvalvular Stenosis; Obstructive Cardiomyopathies, Hypertrophic; Obstructive Cardiomyopathy, Hypertrophic; Obstructive cardiomyopathy; Primary hypertrophic cardiomyopathy; Septal Hypertrophies, Asymmetric; Septal Hypertrophy, Asymmetric; Subvalvular Stenosis, Idiopathic Hypertrophic
PharmGKB Accession Id: PA443633
External Vocabularies

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

Contraindicated With

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy, Dilated

Publications related to Cardiomyopathy, Hypertrophic: 8

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in medicine : official journal of the American College of Medical Genetics. 2013. Green Robert C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nature medicine. 2008. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. The New England journal of medicine. 2007. Kollberg Gittan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature genetics. 2007. Pandit Bhaswati, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nature genetics. 2007. Razzaque M Abdur, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. American journal of human genetics. 2007. He M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. American journal of human genetics. 2006. Smeitink Jan A M, et al. PubMed